Drugs / Dutogliptin
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01101945 | Jul 2007 → Jan 2010 | type 2 diabetes mellitus | Phenomix | Terminated | No outcome recorded |
| Phase 2 | NCT00482950 | Apr 2007 → Feb 2008 | type 2 diabetes mellitus | Phenomix | Unknown | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT01089790 | Mar → Aug 2010 | type 2 diabetes mellitus | Forest Laboratories | Terminated | No outcome recorded |
| Phase 3 | NCT00998686 | Nov 2009 → Oct 2011 | type 2 diabetes mellitus | Phenomix | Terminated | No outcome recorded |
| Phase 3 | NCT00970424 | Aug 2009 → Aug 2010 | type 2 diabetes mellitus | Forest Laboratories | Terminated | No outcome recorded |
| Phase 3 | NCT00958269 | Aug 2009 → Sep 2011 | impaired renal function disease, type 2 diabetes mellitus | Phenomix | Terminated | No outcome recorded |
| Phase 3 | NCT00850239 | May 2009 → Oct 2010 | type 2 diabetes mellitus | Phenomix | Terminated | No outcome recorded |
| Phase 3 | NCT00865592 | Mar 2009 → Jan 2011 | type 2 diabetes mellitus | Phenomix | Terminated | No outcome recorded |
| Phase 3 | NCT00690638 | Jul 2008 → Jan 2010 | type 2 diabetes mellitus | Phenomix | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03486080 Comparator | Dec 2018 → Feb 2021 | ST-elevation myocardial infarction, myocardial ischemia | Recardio, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00530881 Comparator | Apr → Oct 2006 | type 2 diabetes mellitus | Phenomix | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05881382 Comparator | Sep 2023 → Sep 2025 | ST-elevation myocardial infarction | Recardio, Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT00947557 Comparator | Jul 2009 → Jul 2010 | type 2 diabetes mellitus | Forest Laboratories | Terminated | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dutogliptin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03486080 ↗ |
| Known as | DUTOGLIPTIN TARTRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4296719 ↗ |
| Known as | Dutogliptina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4296719 ↗ |
| Known as | Dutogliptine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4296719 ↗ |
| Known as | PHX1149 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00530881 ↗ |
| Known as | PHX1149T | “The purpose of this study is to demonstrate that dutogliptin/PHX1149T is safe and tolerable.” NCT01101945 ↗ |
| Action | Inhibit | “The drug is a "DPP4 inhibitor"” NCT00530881 ↗ |
| Modality | Small molecule | — CHEMBL4296719 ↗ |
| Route | Oral | “oral administration once daily” NCT00947557 ↗ |
| Target | DPP4 | “The drug is a "DPP4 inhibitor"” NCT00530881 ↗ |